SCHEMBL3449698

SCHEMBL3449698

CON(C)C(=O)c1cccc(OBOc2cccc(C(=O)N(C)OC)c2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.45
CES1 P23141 1/20 0.45
HSD17B2 P37059 1/20 0.43
PARP1 P09874 1/20 0.42
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
ABCG2 Q9UNQ0 1/20 0.40
MLYCD O95822 1/20 0.40
MAOB P27338 3/20 0.40
MAOA P21397 1/20 0.40
CDK4 P11802 1/20 0.39
CCND1 P24385 1/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
ALDH1A1 P00352 1/20 0.38
BCHE P06276 1/20 0.38
ACHE P22303 1/20 0.38
CLK1 P49759 1/20 0.38
DYRK1A Q13627 1/20 0.38
DYRK1B Q9Y463 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL177413 0.85 F10 (0.48) CES2CES1HSD17B2PARP1MEN1
SCHEMBL307622 0.85 CES2 (0.62) CES2CES1HSD17B2PARP1MEN1
SCHEMBL15281239 0.83 KMT2A (0.50) CES2CES1HSD17B2PARP1MEN1
SCHEMBL25720168 0.80 LMNA (0.50) MEN1KMT2ANPC1RAB9AALDH1A1
SCHEMBL1557170 0.79 HDAC8 (0.53) CES2CES1MLYCDMAOBNPC1
SCHEMBL6359076 0.79 KMT2A (0.43) CES2CES1HSD17B2PARP1MEN1
SCHEMBL16214051 0.78 MEN1 (0.46) CES2CES1HSD17B2MEN1KMT2A
SCHEMBL5095020 0.78 HPGD (0.59) NPC1RAB9AALDH1A1CYP1A2
SCHEMBL289656 0.78 KMT2A (0.57) CES2CES1PARP1MEN1KMT2A
SCHEMBL30678242 0.78 NPC1 (0.49) CES2CES1KMT2AMAOBNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD CES2 587/4885CES1 1511/4885HSD17B2 485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.